In summary, our results showed that the content of mutant EGFR DNA is associated with the clinical response to EGFR-TKIs in lung adenocarcinoma patients with common EGFR mutations, especially in patients with exon 19 deletion mutations. The gene discussed is EGFR; the disease is lung adenocarcinoma.